Business Wire

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions

Share

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets

Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions.

By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions.

At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single point of control for compliance, risk analytics, and strategic decision-making. RRiskHub will unite Regnology’s established regulatory reporting and core risk expertise with comprehensive risk quantification and ALM offerings acquired from Moody’s, combining specialized capabilities around financial risk measurement, capital, liquidity management, and multi-jurisdictional reporting. The combined offering sets a new standard for all-in-one regulatory and risk solutions.

Built on the Regnology Granular Data (RGD) model for consistency, auditability, and scalability across risk and regulatory domains, supported by Regnology’s secure, cloud-native platform, the Regnology Risk Hub empowers Chief Risk Officers with actionable control and oversight through integrated automation, AI-driven insights for future-ready operations, and continuous innovation.

Rob Mackay, CEO of Regnology, said: “The proposed acquisition of Moody’s Regulatory Reporting & ALM Solutions is a bold step forward in our mission to be at the forefront of the regulatory and risk technology space. This acquisition strengthens our shared commitment to deliver transformative value and help Chief Risk Officers and Chief Financial Officers navigate an increasingly complex landscape with confidence. We are looking forward to further advancing our platform to empower financial institutions worldwide with innovative solutions, while opening new horizons for our customers and employees to thrive.”

Fredrik Näslund, Partner, Nordic Capital Advisors, commented: “Nordic Capital is delighted to support Regnology as it continues its impressive growth journey. This acquisition underscores Regnology’s strong accelerating progress within the regulatory technology sector to further deliver outstanding solutions to financial institutions around the world.”

Andrew Bockelman, Head of Banking Solutions for Moody’s, said: “We are grateful for the work of our teams that have built these solutions over the years, and we are confident they are joining an organization that will continue to provide top-rate service to customers and new growth opportunities for employees. Regnology is strategically positioned to build on the strengths of these product families, while Moody’s continues to focus on its core lending, credit modeling, KYC, financial crime, portfolio risk, and data-driven solutions.”

The proposed acquisition remains subject to consultation with the relevant works councils and is further subject to obtaining regulatory approvals in several jurisdictions.

About Regnology

Regnology is a recognized leader in regulatory, risk, tax, and finance reporting technology— connecting regulators and the regulated across more than 100 countries. Our unique position enables us to span the full spectrum of industry needs, delivering solutions that address both oversight and compliance requirements to a broad range of clients, including global Tier 1 banks, local and regional institutions, corporates, insurers, and authorities.

With a presence in over 30 countries and deep local expertise, Regnology combines a truly global approach with an understanding of regional regulatory requirements. Our unified data model and “map once, report many” methodology ensure consistency, auditability, and scalability across jurisdictions, while our modular, cloud-native solutions empower clients to achieve compliance, unlock enterprise-wide insights, and future-proof their operations.

Regnology’s leadership is underpinned by fast-paced growth and a front-running approach to innovation, continually investing in automation, AI, and domain expertise to deliver future-ready solutions.

For more information about Regnology, connect with us on LinkedIn.

Visit our website: www.regnology.net.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251218771396/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye